A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis

Summary

This is an open label, multicenter study designed to evaluate the safety and tolerability of ATI-502 Topical Solution in male and female subjects with moderate or severe atopic dermatitis (AD). Subjects will be required to apply ATI-502 study medication to their identified AD treatment areas. All subjects will be required to complete a safety follow up visit 4 weeks post last study medication application

Timeline

Start

2018-07-10

Primary completion

2019-04-25

Completion

2019-04-25

Drugs

Indications